Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses

L. La Mantia, M. Eoli, C. Milanese, A. Salmaggi, A. Dufour, V. Torri

Research output: Contribution to journalArticle

Abstract

The efficacy of dexamethasone (DX) and methylprednisolone (MP) at high (HD) and low (LD) dose in acute multiple sclerosis (MS) relapses was evaluated by a double-blind trial in 31 patients followed for 1 year. DX and HDMP were similarly efficacious in promoting recovery, while LDMP was ineffective in the short-term outcome and was followed by an early clinical reactivation. The different outcomes seem to be related to different immunomodulating effects, mainly on cerebrospinal fluid (CSF) IgG synthesis and on peripheral blood and CSF CD4+ lymphocyte subsets.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalEuropean Neurology
Volume34
Issue number4
DOIs
Publication statusPublished - 1994

Keywords

  • Multiple sclerosis
  • Relapse
  • Steroids

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses'. Together they form a unique fingerprint.

  • Cite this